Built for the questions your team asks every day.
Here's what that looks like in practice.
→ 2 minutes
(Bayezian AI)
→ 3 minutes
(Nasdaq listed biotech)
Prospects and partners you'd never find manually.
Bayezian AI had an extensive set of criteria for the companies they target, but no way to run those criteria in an automated process. They were finding likely candidates manually, often taking days, then checking whether each one fit.
With RxClarity, we studied their criteria and split match signals into "strong" and "soft" signals. We screened hundreds of companies down to 10 strong prospect matches and several on a watch list, each tagged with the exact signal that triggered it, and surfacing companies their manual search had missed.
“RxClarity is significantly faster than our current process, and found companies we never would have identified.”
Keep a live competitive comparison your team actually decides on.
A clinical-stage biotech needed to track trials in a specific disease area and compare everything from the drugs tested and biomarker strategy to reported outcomes.
RxClarity built an agent to run that analysis and keep the report current as the underlying evidence changes and grows.
“I really enjoyed working with RxClarity. I learned a lot and found it extremely valuable.”
Catch what's quietly at risk before the readout.
Slipping completion dates, upcoming patent cliffs, competitor readouts or M&A: the signals that a program or asset may need attention before it is announced. RxClarity watches continuously across all therapy areas and flags each risk signal with the reason and a next step.